Aurobindo Pharma Announcements
Submission of transcript of earning call held on February 10, 2026 for Q3 FY2025-26 financial results.
16 Feb, 2026 | 11:17am • Source: BSE
Submission of the copies of notice published by the Company on February 13, 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement...
13 Feb, 2026 | 11:43am • Source: BSE
Submission of copies of newspaper advertisement of the financial results of the Company for the third quarter and nine months period ended December 31, 2025...
11 Feb, 2026 | 11:51am • Source: BSE
Intimation of completion of US FDA inspection at Unit VII of the Company at Jedcherla.
10 Feb, 2026 | 10:04pm • Source: BSE
Aurobindo Pharma Limited has informed the Exchange about Investor Presentation
10 Feb, 2026 | 11:12am • Source: NSE
Outcome of Board meeting held on February 9, 2026
09 Feb, 2026 | 07:21pm • Source: BSE
Intimation of completion of US FDA inspection at Unit III of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
06 Feb, 2026 | 06:22pm • Source: BSE
Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
05 Feb, 2026 | 12:35pm • Source: NSE
Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
05 Feb, 2026 | 12:30pm • Source: NSE
Intimation of participation in Axis Capital''s India Investor Conference to be held on February 12, 2026.
05 Feb, 2026 | 12:02pm • Source: BSE
Intimation of participation in Nuvama's India Investor Conference to be held on February 11, 2026.
05 Feb, 2026 | 12:00pm • Source: BSE
Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
02 Feb, 2026 | 11:08am • Source: NSE
Intimation of date of earning call on the Unaudited Financial Results for the third quarter and nine months period ended December 31, 2025.
02 Feb, 2026 | 10:27am • Source: BSE
Submission of clarification on significant volume movement in Company''s shares.
02 Feb, 2026 | 10:07am • Source: BSE
The Exchange has sought clarification from Aurobindo Pharma Ltd on February 01, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
01 Feb, 2026 | 12:37pm • Source: BSE
Submission of clarification on significant volume movement in Company''s shares sought vide letter No.NSE/CM/Surveilance/16398 dated January 30, 2026.
31 Jan, 2026 | 11:16am • Source: BSE
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider and...
30 Jan, 2026 | 04:43pm • Source: BSE
Intimation of incorporation of new step-down Subsidiary in Philippines.
23 Jan, 2026 | 05:09pm • Source: BSE
Intimation of receipt of Notice of Compliance from Health Canada by Curateq Biologics Private Limited, a wholly owned subsidiary of the Company for its biosimilar...
09 Jan, 2026 | 03:19pm • Source: BSE
Intimation of plant visit by investors.
08 Jan, 2026 | 05:16pm • Source: BSE